GLP-1 effects on menstrual cycles add another variable
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in early T2D management due to their glycemic and weight-reducing effects
In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease
At clinical trial dosing of 8 to 12mg per week, research peptide costs translate to roughly $150 to $500 per month
Shipping, storage, quality, and when to speak to a clinician without the runaround
FDA Targets GLP-1 Providers with Warning Letters GLP-1 Drugs: FDA Removes Lillys Zepbound and Mounjaro (semaglutide injection) from its Drug Shortage List GLP-1 Drugs: Brand Companies Push FDA to Limit Compounding Foley will continue to monitor these developments
